Rallybio (NASDAQ:RLYB) Issues Earnings Results

Rallybio (NASDAQ:RLYB) posted its quarterly earnings results on Monday. The company reported ($1.03) EPS for the quarter, beating analysts’ consensus estimates of ($1.04) by $0.01, FiscalAI reports. Rallybio had a negative return on equity of 65.23% and a negative net margin of 2,102.37%.The business had revenue of $0.22 million for the quarter, compared to analysts’ expectations of $0.10 million.

Rallybio Price Performance

RLYB stock traded down $0.09 during mid-day trading on Monday, reaching $9.41. The company had a trading volume of 123,701 shares, compared to its average volume of 140,824. The firm has a 50 day moving average of $6.30 and a 200 day moving average of $5.47. The company has a market capitalization of $49.71 million, a PE ratio of -3.68 and a beta of -1.13. Rallybio has a 12 month low of $1.76 and a 12 month high of $11.49.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rallybio in a report on Monday, December 29th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and a consensus target price of $40.00.

Institutional Trading of Rallybio

A number of hedge funds have recently bought and sold shares of RLYB. Renaissance Technologies LLC raised its stake in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock worth $573,000 after acquiring an additional 120,892 shares in the last quarter. Citadel Advisors LLC grew its holdings in Rallybio by 576.1% in the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock worth $219,000 after purchasing an additional 373,821 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares in the last quarter. Susquehanna International Group LLP lifted its holdings in shares of Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock valued at $68,000 after purchasing an additional 113,031 shares during the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Rallybio by 64.6% during the 4th quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock valued at $67,000 after purchasing an additional 38,205 shares during the last quarter. Hedge funds and other institutional investors own 90.34% of the company’s stock.

Rallybio Company Profile

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.